FORT LAUDERDALE, Fla., July 2 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., a pioneer in laser optical breast imaging systems, announced that IDSI Beijing will exhibit CT Laser Mammography (CTLM(R)) clinical results at the 21st Annual China National Medical Imaging Technology Research Seminar, June 29-July 3, in Mudanjiang City, Heilongjiang Province, China.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO)
A select group of 200 of China’s leading medical imaging experts are invited by the organizers, the China Medical Imaging Technology Association, to attend the seminar.
IMDS is continuing to increase the visibility of its CTLM system in China by attending scientific sessions, medical expositions, and individual presentations to familiarize potential users with unique new functional imaging capabilities. IDSI Beijing, the company’s new direct operation, provides marketing, administrative, and service and distributor support for these efforts.
The CTLM system has received approval for sale from the State Food and Drug Administration of the People’s Republic of China (SFDA), the Chinese equivalent of the US Food and Drug Administration. In the Beijing region, CTLM breast imaging procedures are approved for patient charges.
About Imaging Diagnostic Systems, Inc.
Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLMâ system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM(R)) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.
Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) application for the Computed Tomography Laser Mammography (CTLM(R)) system to be used as an adjunct to mammography. The FDA has determined that the Company’s clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.
For more information, visit our website: www.imds.com
As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.
Investor Relations: Rick Lutz (404) 261-1196 lcgroup@mindspring.com Media Contact: Elizabeth Williams (954) 581-9800 williams@imds.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comImaging Diagnostic Systems, Inc.
CONTACT: Investor Relations, Rick Lutz , +1-404-261-1196,lcgroup@mindspring.com; or Media, Elizabeth Williams, +1-954-581-9800,williams@imds.com
Web site: http://www.imds.com//